Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

(-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells
Peng Fu, Liang Xiong, Cheng Peng
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 56

Showing 1-25 of 56 citing articles:

Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies
Minru Liao, Rui Qin, Wei Huang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 89
Chemistry, pharmacokinetics, pharmacological activities, and toxicity of Quercitrin
Junren Chen, Gangmin Li, Chen Sun, et al.
Phytotherapy Research (2022) Vol. 36, Iss. 4, pp. 1545-1575
Closed Access | Times Cited: 76
MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways
Arefeh Zabeti Touchaei, Sogand Vahidi
Cancer Cell International (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 28
Ferroptosis in Non-Small Cell Lung Cancer: Progression and Therapeutic Potential on It
Jiayu Zou, Li Wang, Hailin Tang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13335-13335
Open Access | Times Cited: 73
New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
Junsha An, Cheng Peng, Hailin Tang, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9644-9644
Open Access | Times Cited: 62
Targeting PD-1/PD-L1 in cancer immunotherapy: An effective strategy for treatment of triple-negative breast cancer (TNBC) patients
Sunny Kumar, Mouli Chatterjee, Pratyasha Ghosh, et al.
Genes & Diseases (2022) Vol. 10, Iss. 4, pp. 1318-1350
Open Access | Times Cited: 43
PD-L1: expression regulation
Yujie Zhou, Guoli Li, Jiyin Wang, et al.
Blood Science (2023) Vol. 5, Iss. 2, pp. 77-91
Open Access | Times Cited: 26
Progress in the Regulation of Immune Cells in the Tumor Microenvironment by Bioactive Compounds of Traditional Chinese Medicine
Yuqian Chen, Wenshuang Fan, Yanyan Zhao, et al.
Molecules (2024) Vol. 29, Iss. 10, pp. 2374-2374
Open Access | Times Cited: 8
PD-1/PD-L1 axis regulation in cancer therapy: The role of long non-coding RNAs and microRNAs
Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, et al.
Life Sciences (2020) Vol. 256, pp. 117899-117899
Closed Access | Times Cited: 65
miRNA-Based Therapeutics in Breast Cancer: A Systematic Review
Anna Grimaldi, Marco Salvatore, Mariarosaria Incoronato
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 50
A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery
Mahdi Abdoli Shadbad, Sahar Safaei, Oronzo Brunetti, et al.
Genes (2021) Vol. 12, Iss. 8, pp. 1206-1206
Open Access | Times Cited: 48
Natural products and their derivatives as immune check point inhibitors: Targeting cytokine/chemokine signalling in cancer
Meenakshi Gupta, Kumari Chandan, Maryam Sarwat
Seminars in Cancer Biology (2022) Vol. 86, pp. 214-232
Closed Access | Times Cited: 32
Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy
Kunjing Liu, Qi Sun, Qi Liu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113618-113618
Open Access | Times Cited: 31
Natural Products as Novel Therapeutic Agents for Triple-Negative Breast Cancer: Current Evidence, Mechanisms, Challenges, and Opportunities
Qingzhou Li, Zhen Ye, Guilin Wang, et al.
Molecules (2025) Vol. 30, Iss. 6, pp. 1201-1201
Open Access
Development of natural products for anti-PD-1/PD-L1 immunotherapy against cancer
MyongHak Ri, Juan Ma, Xuejun Jin
Journal of Ethnopharmacology (2021) Vol. 281, pp. 114370-114370
Closed Access | Times Cited: 33
The Antitriple Negative Breast cancer Efficacy of Spatholobus suberectus Dunn on ROS‐Induced Noncanonical Inflammasome Pyroptotic Pathway
Feng Zhang, Qingqing Liu, Kumar Ganesan, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 32
Maackiain Modulates miR-374a/GADD45A Axis to Inhibit Triple-Negative Breast Cancer Initiation and Progression
Fu Peng, Li Wang, Liang Xiong, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 24
Modulation of AKT Pathway-Targeting miRNAs for Cancer Cell Treatment with Natural Products
Jun‐Ping Shiau, Ya-Ting Chuang, Ching‐Yu Yen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3688-3688
Open Access | Times Cited: 12
Advances in traditional Chinese herbal medicine and their pharmacodynamic mechanisms in cancer immunoregulation: a narrative review
Ruishan Wen, Xiulian Huang, Jinyu Long, et al.
Translational Cancer Research (2024) Vol. 13, Iss. 2, pp. 1166-1187
Open Access | Times Cited: 4
The Anticancer Potential of Maslinic Acid and Its Derivatives: A Review
Lei Yu, Xiaofang Xie, Xiaoyu Cao, et al.
Drug Design Development and Therapy (2021) Vol. Volume 15, pp. 3863-3879
Open Access | Times Cited: 27
Aerosolized miR-138-5p and miR-200c targets PD-L1 for lung cancer prevention
Qi Zhang, Jing Pan, Donghai Xiong, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Despicable role of epithelial–mesenchymal transition in breast cancer metastasis: Exhibiting de novo restorative regimens
Paras Famta, Saurabh Shah, Biswajit Dey, et al.
Cancer Pathogenesis and Therapy (2024) Vol. 3, Iss. 1, pp. 30-47
Open Access | Times Cited: 3
Nature’s Arsenal: Harnessing the Capacity of Phytochemicals to Enhance Immune Checkpoint Inhibitor Therapy of Cancers: An Especial Attention to Brain Malignancies
Amir R. Afshari, Mehdi Sanati, Seyed Sajad Ahmadi, et al.
Cancer Letters (2024) Vol. 593, pp. 216955-216955
Closed Access | Times Cited: 3
Biochanin A from Chinese Medicine: An Isoflavone with Diverse Pharmacological Properties
Yan Jia, Panda Qiu, Xinyu Zhang, et al.
The American Journal of Chinese Medicine (2021) Vol. 49, Iss. 07, pp. 1623-1643
Closed Access | Times Cited: 25
Polyphenols Modulating Effects of PD-L1/PD-1 Checkpoint and EMT-Mediated PD-L1 Overexpression in Breast Cancer
Samia S. Messeha, Najla O. Zarmouh, Karam F. A. Soliman
Nutrients (2021) Vol. 13, Iss. 5, pp. 1718-1718
Open Access | Times Cited: 23
Page 1 - Next Page

Scroll to top